MCL1 and prostate cancer: Shimizu et al. identified a mechanism in which MCL-1 stability is increased in breast and prostate cancer cell lines through acetylation by p300, which enhances the de-ubiquitinating function of USP9X, facilitating apoptosis evasion [25].